In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Agilent exercises option to acquire remaining 52% in Lasergen for $105mm

Executive Summary

Agilent Technologies Inc. exercised its option to acquire the remaining 52% not already owned in Lasergen Inc. for $105mm.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech
    • Intra-Biotech Deal
    • Partial Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register